Rigontec
Martinsried
About Rigontec
Rigontec is the leader in RIG-I targeting RNA therapeutics developing novel immuno-oncology treatment options.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $34.1M
- Funding stage: M&A
- Last round: Series A (Sep 2016)
- Website: rigontec.com
- Phone: +498920006640
Industries & Categories
Biotechnology, Health Care, Medical, Oncology, Therapeutics
Canonical: https://fsome.com/organization/rigontec-180662 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.